{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,8]],"date-time":"2026-09-08T23:34:58Z","timestamp":1788910498201,"version":"build-2803163510"},"reference-count":14,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2021,7,1]],"date-time":"2021-07-01T00:00:00Z","timestamp":1625097600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,7,1]],"date-time":"2021-07-01T00:00:00Z","timestamp":1625097600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","clinical-lung-cancer.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Lung Cancer"],"published-print":{"date-parts":[[2021,7]]},"DOI":"10.1016\/j.cllc.2020.11.007","type":"journal-article","created":{"date-parts":[[2020,12,2]],"date-time":"2020-12-02T02:54:37Z","timestamp":1606877677000},"page":"e519-e527","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":11,"title":["Treatment of Non\u2013Small-Cell Lung Cancer Based on Circulating Cell-Free DNA and Impact of Variation Allele Frequency"],"prefix":"10.1016","volume":"22","author":[{"given":"Jean G.","family":"Bustamante Alvarez","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sarah","family":"Janse","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6598-4886","authenticated-orcid":false,"given":"Dwight H.","family":"Owen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephanie","family":"Kiourtsis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Erin M.","family":"Bertino","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kai","family":"He","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David P.","family":"Carbone","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gregory A.","family":"Otterson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.cllc.2020.11.007_bib1","doi-asserted-by":"crossref","first-page":"504","DOI":"10.6004\/jnccn.2017.0050","article-title":"Non\u2013small cell lung cancer, version 5.2017: NCCN Clinical Practice Guidelines in Oncology","volume":"15","author":"Ettinger","year":"2017","journal-title":"J\u00a0Natl Compr Canc Netw"},{"key":"10.1016\/j.cllc.2020.11.007_bib2","doi-asserted-by":"crossref","first-page":"1248","DOI":"10.1016\/j.jtho.2018.05.030","article-title":"Liquid biopsy for advanced non\u2013small cell lung cancer (NSCLC): a statement paper from the IASLC","volume":"13","author":"Rolfo","year":"2018","journal-title":"J\u00a0Thorac Oncol"},{"key":"10.1016\/j.cllc.2020.11.007_bib3","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1016\/j.jtho.2017.12.001","volume":"13","author":"Lindeman","year":"2018","journal-title":"J\u00a0Thorac Oncol"},{"key":"10.1016\/j.cllc.2020.11.007_bib4","doi-asserted-by":"crossref","first-page":"4691","DOI":"10.1158\/1078-0432.CCR-19-0624","article-title":"Clinical utility of comprehensive cell-free DNA analysis to identify genomic biomarkers in patients with newly diagnosed metastatic non\u2013small cell lung cancer","volume":"25","author":"Leighl","year":"2019","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.cllc.2020.11.007_bib5","doi-asserted-by":"crossref","first-page":"7526","DOI":"10.1038\/s41598-017-06106-1","article-title":"Statistical analysis of mutant allele frequency level of circulating cell-free DNA and blood cells in healthy individuals","volume":"7","author":"Xia","year":"2017","journal-title":"Sci Rep"},{"key":"10.1016\/j.cllc.2020.11.007_bib6","doi-asserted-by":"crossref","first-page":"2240","DOI":"10.1158\/1078-0432.CCR-12-2246","article-title":"Analysis of tumor specimens at the time of acquired resistance to EGFR-TKI therapy in 155 patients with EGFR-mutant lung cancers","volume":"19","author":"Yu","year":"2013","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.cllc.2020.11.007_bib7","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1056\/NEJMoa1713137","article-title":"Osimertinib in untreated EGFR-mutated advanced non\u2013small-cell lung cancer","volume":"378","author":"Soria","year":"2018","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.cllc.2020.11.007_bib8","doi-asserted-by":"crossref","first-page":"278","DOI":"10.1200\/JCO.18.01585","article-title":"EGFR-mutant adenocarcinomas that transform to small-cell lung cancer and other neuroendocrine carcinomas: clinical outcomes","volume":"37","author":"Marcoux","year":"2019","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.cllc.2020.11.007_bib9","doi-asserted-by":"crossref","first-page":"349","DOI":"10.21037\/atm.2019.03.28","article-title":"Liquid biopsy for lung cancers: an update on recent developments","volume":"7","author":"Revelo","year":"2019","journal-title":"Ann Transl Med"},{"issue":"suppl","key":"10.1016\/j.cllc.2020.11.007_bib10","doi-asserted-by":"crossref","first-page":"9005","DOI":"10.1200\/JCO.2019.37.15_suppl.9005","article-title":"Phase II study of tepotinib in NSCLC patients with METex14 mutations","volume":"37","author":"Paik","year":"2019","journal-title":"J\u00a0Clin Oncol"},{"issue":"15 suppl","key":"10.1016\/j.cllc.2020.11.007_bib11","doi-asserted-by":"crossref","first-page":"9004","DOI":"10.1200\/JCO.2019.37.15_suppl.9004","article-title":"Capmatinib (INC280) in MET\u0394ex14-mutated advanced non\u2013small cell lung cancer (NSCLC): efficacy data from the phase II GEOMETRY mono-1 study","volume":"37","author":"Wolf","year":"2019","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.cllc.2020.11.007_bib12","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1186\/s12943-018-0789-x","article-title":"KRAS oncogene in non\u2013small cell lung cancer: clinical perspectives on the treatment of an old target","volume":"17","author":"Roman","year":"2018","journal-title":"Mol Cancer"},{"key":"10.1016\/j.cllc.2020.11.007_bib13","doi-asserted-by":"crossref","first-page":"4273","DOI":"10.1158\/1078-0432.CCR-13-0318","article-title":"ALK rearrangements are mutually exclusive with mutations in EGFR or KRAS: an analysis of 1,683 patients with non\u2013small cell lung cancer","volume":"19","author":"Gainor","year":"2013","journal-title":"Clin Cancer Res"},{"issue":"15 suppl","key":"10.1016\/j.cllc.2020.11.007_bib14","doi-asserted-by":"crossref","first-page":"3003","DOI":"10.1200\/JCO.2019.37.15_suppl.3003","article-title":"Phase 1 study evaluating the safety, tolerability, pharmacokinetics (PK), and efficacy of AMG 510, a novel small molecule KRASG12C inhibitor, in advanced solid tumors","volume":"37","author":"Fakih","year":"2019","journal-title":"J\u00a0Clin Oncol"}],"container-title":["Clinical Lung Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1525730420303405?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1525730420303405?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,26]],"date-time":"2025-10-26T19:10:54Z","timestamp":1761505854000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1525730420303405"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,7]]},"references-count":14,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2021,7]]}},"alternative-id":["S1525730420303405"],"URL":"https:\/\/doi.org\/10.1016\/j.cllc.2020.11.007","relation":{},"ISSN":["1525-7304"],"issn-type":[{"value":"1525-7304","type":"print"}],"subject":[],"published":{"date-parts":[[2021,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Treatment of Non\u2013Small-Cell Lung Cancer Based on Circulating Cell-Free DNA and Impact of Variation Allele Frequency","name":"articletitle","label":"Article Title"},{"value":"Clinical Lung Cancer","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.cllc.2020.11.007","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2020 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}